{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:40Z","timestamp":1707525100144},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"DOI":"10.7759\/cureus.40140","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:12:35Z","timestamp":1686247955000},"source":"Crossref","is-referenced-by-count":0,"title":["Influence of Thyroid Peroxidase Antibodies Serum Levels in Graves' Disease: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Maria L","family":"Guia Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Tavares Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 P","family":"Cidade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Limbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao","family":"Sequeira Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves' disease: a single center experience","volume":"44","author":"Anagnostis P","year":"2013","unstructured":"Anagnostis P, Adamidou F, Polyzos SA, et al.. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine. 2013, 44:448-53. 10.1007\/s12020-013-9895-0","journal-title":"Endocrine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly GJ","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J. 2018, 7:167-86. 10.1159\/000490384","journal-title":"Eur Thyroid J"},{"key":"ref3","article-title":"Endocrinologia Clinica - 6 edicao (Book in Portugese)","author":"Vilar L","year":"2006","unstructured":"Vilar L. Endocrinologia Clinica - 6 edicao (Book in Portugese). 2006."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.05.009","article-title":"Thyrotropin receptor autoantibodies in Graves' disease","volume":"16","author":"Schott M","year":"2005","unstructured":"Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves' disease. Trends Endocrinol Metab. 2005, 16:243-8. 10.1016\/j.tem.2005.05.009","journal-title":"Trends Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2015.29.4.213","article-title":"Clinical Association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves\u2019 orbitopathy","volume":"29","author":"Woo YJ","year":"2015","unstructured":"Woo YJ, Jang SY, Lim TH, Yoon JS. Clinical Association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves\u2019 orbitopathy. Korean J Ophthalmol. 2015, 29:213-9. 10.3341\/kjo.2015.29.4.213","journal-title":"Korean J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross DS","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al.. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016, 26:1343-421. 10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1535","article-title":"Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study","volume":"121","author":"Glaser NS","year":"2008","unstructured":"Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008, 121:e481-8. 10.1542\/peds.2007-1535","journal-title":"Pediatrics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0047","article-title":"TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves' disease","volume":"11","author":"Verdickt S","year":"2022","unstructured":"Verdickt S, Van Nes F, Moyson C, Maes T, Van Crombrugge P, Van den Bruel A, Decallonne B. TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves' disease. Eur Thyroid J. 2022, 11:10.1530\/ETJ-22-0047","journal-title":"Eur Thyroid J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2019.416","article-title":"Williams Textbook of Endocrinology","volume":"15","author":"Badiu C","year":"2019","unstructured":"Badiu C. Williams Textbook of Endocrinology. Acta Endocrinol (Buchar). 2019, 15:416. 10.4183\/aeb.2019.416","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100293","article-title":"Epitopes specificity of antibodies to thyroid peroxidase in patients with Graves' disease, Hashimoto's thyroiditis and overlap-syndrome","volume":"27","author":"Espenbetova M","year":"2022","unstructured":"Espenbetova M, Kuzmina N, Zubkov A, et al.. Epitopes specificity of antibodies to thyroid peroxidase in patients with Graves' disease, Hashimoto's thyroiditis and overlap-syndrome. J Clin Transl Endocrinol. 2022, 27:100293. 10.1016\/j.jcte.2022.100293","journal-title":"J Clin Transl Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb05749.x","article-title":"Anti-thyroid peroxidase antibodies in sera from healthy subjects and from patients with chronic thyroiditis: differences in the ability to inhibit thyroid peroxidase activities","volume":"85","author":"Kohno Y","year":"1991","unstructured":"Kohno Y, Yamaguchi F, Saito K, Niimi H, Nishikawa T, Hosoya T. Anti-thyroid peroxidase antibodies in sera from healthy subjects and from patients with chronic thyroiditis: differences in the ability to inhibit thyroid peroxidase activities. Clin Exp Immunol. 1991, 85:459-63. 10.1111\/j.1365-2249.1991.tb05749.x","journal-title":"Clin Exp Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/43.8.1392","article-title":"Effect of anti-thyroid peroxidase (TPO) antibodies on TPO activity measured by chemiluminescence assay","volume":"43","author":"Kaczur V","year":"1997","unstructured":"Kaczur V, Vereb G, Moln\u00e1r I, et al.. Effect of anti-thyroid peroxidase (TPO) antibodies on TPO activity measured by chemiluminescence assay. Clin Chem. 1997, 43:1392-6. 10.1093\/clinchem\/43.8.1392","journal-title":"Clin Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2004.01.007","article-title":"Hyperthyroidism: advantages and disadvantages of medical therapy","volume":"84","author":"Pearce EN","year":"2004","unstructured":"Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am. 2004, 84:833-47. 10.1016\/j.suc.2004.01.007","journal-title":"Surg Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-012-0028-1","article-title":"Blocking type TSH receptor antibodies","volume":"4","author":"Furmaniak J","year":"2013","unstructured":"Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. Auto Immun Highlights. 2013, 4:11-26. 10.1007\/s13317-012-0028-1","journal-title":"Auto Immun Highlights"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.579","article-title":"The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease","volume":"10","author":"Kim WB","year":"2000","unstructured":"Kim WB, Chung HK, Park YJ, Park DJ, Tahara K, Kohn LD, Cho BY. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease. Thyroid. 2000, 10:579-86. 10.1089\/thy.2000.10.579","journal-title":"Thyroid"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0017","article-title":"Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse","volume":"26","author":"Tun NN","year":"2016","unstructured":"Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW. Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse. Thyroid. 2016, 26:1004-9. 10.1089\/thy.2016.0017","journal-title":"Thyroid"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-957347","article-title":"Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies","volume":"39","author":"Schott M","year":"2007","unstructured":"Schott M, Eckstein A, Willenberg HS, Nguyen TB, Morgenthaler NG, Scherbaum WA. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies. Horm Metab Res. 2007, 39:56-61. 10.1055\/s-2007-957347","journal-title":"Horm Metab Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0035","article-title":"Thyroid peroxidase antibody positivity is associated with relapse-free survival following antithyroid drug treatment for Graves disease","volume":"26","author":"Muir CA","year":"2020","unstructured":"Muir CA, Jones GR, Greenfield JR, Weissberger A, Samaras K. Thyroid peroxidase antibody positivity is associated with relapse-free survival following antithyroid drug treatment for Graves disease. Endocr Pract. 2020, 26:1026-30. 10.4158\/EP-2020-0035","journal-title":"Endocr Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00521","article-title":"Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases","volume":"8","author":"Fr\u00f6hlich E","year":"2017","unstructured":"Fr\u00f6hlich E, Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017, 8:521. 10.3389\/fimmu.2017.00521","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408042200","article-title":"Endoproteolytic cleavage of human thyroperoxidase: role of the propeptide in the protein folding process","volume":"280","author":"Le Fourn V","year":"2005","unstructured":"Le Fourn V, Ferrand M, Franc JL. Endoproteolytic cleavage of human thyroperoxidase: role of the propeptide in the protein folding process. J Biol Chem. 2005, 280:4568-77. 10.1074\/jbc.M408042200","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1140328","article-title":"Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves' disease","volume":"114","author":"Hamada N","year":"1987","unstructured":"Hamada N, Ito K, Mimura T, et al.. Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves' disease. Acta Endocrinol (Copenh). 1987, 114:328-35. 10.1530\/acta.0.1140328","journal-title":"Acta Endocrinol (Copenh)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.268","article-title":"Changes in thyroid peroxidase and thyroglobulin antibodies might be associated with Graves' disease relapse after antithyroid drug therapy","volume":"34","author":"Choi YM","year":"2019","unstructured":"Choi YM, Kwak MK, Hong SM, Hong EG. Changes in thyroid peroxidase and thyroglobulin antibodies might be associated with Graves' disease relapse after antithyroid drug therapy. Endocrinol Metab (Seoul). 2019, 34:268-74. 10.3803\/EnM.2019.34.3.268","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160741-influence-of-thyroid-peroxidase-antibodies-serum-levels-in-graves-disease-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:07Z","timestamp":1707508867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160741-influence-of-thyroid-peroxidase-antibodies-serum-levels-in-graves-disease-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.40140","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}